You are here
AIDS Vaccine Conference 2009
AIDS Vaccine 2009 brought together more than 1,000 HIV research scientists, clinicians, epidemiologists and public health experts to share information and address the challenges and opportunities in the field of HIV vaccine development.
The HIV vaccine trial in Thailand, which was led by MHRP, was a major focus at the conference. Dr. Supachai, the principal investigator, and COL Nelson Michael, Director of MHRP, presented detailed results of the trial, which is known as RV144. Mark de Souza, Laboratory Director at AFRIMS, and COL Jerome Kim, MHRP Deputy Director, Science, also made presentations associated with RV144.
Jeff Currier presented data from a Phase I study of a vaccine candidate that was developed by MHRP. His data showed that rMVA-CMDR was safe, well tolerated and immunogenic. He concluded that it is an ideal candidate for future heterologous vector prime-boost vaccination strategies.
The following is a complete list of oral abstracts and posters presented by MHRP staff October 19-22, in Paris, France:
Characterization of Cell-Mediated Immune Responses Generated by rMVA-HIV-1 in a Phase I, Randomized, Placebo Controlled Vaccine Trial – RV158
de Souza, Mark
Immunogenicity of ALVAC-HIV (vCP1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial
Post-Infection Cellular Immune Responses in Recipients Following ALVAC-HIV® + AIDSVAX® B/E Prime-boost Vaccination in the Thai Phase III Trial
HLA-A*7401 is Associated with Protection from HIV-1 Acquisition and Disease Progression in Mbeya, Tanzania
Michael, Nelson L.
Primary and Subgroup Analyses of the Thai Phase III HIV Vaccine Trial
ALVAC®–HIV and AIDSVAX® B/E Prime–Boost HIV–1 Preventive Vaccine Regimen: Final Results of the Phase III Community–based Trial in Thailand
Membrane-specific antibodies that simultaneously bind to gp41 of HIV-1 and membrane lipid epitopes are induced by immunization with liposomes
Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
Full-length IMC expressing Renilla Luciferase for neutralization assay using PBMC
Eller, Leigh Anne
Breath and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or D containing recombinants in Rakai District, Uganda
Altered NK cell phenotype and function in Ugandans with chronic HIV-1 infection
Matyas, Gary Neutralizing antibodies induced by immunization with liposomal hiv-1 gp41, peptide simultaneously binds to both the 2For 4E10 epitope and lipid epitopes
Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
Genetic complexity of trim5 and apobec in East Africa
Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1 and MIP-2
HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific